- Home
- ZYME vs AIO Comparison
ZYME vs AIO Comparison
Compare ZYME & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- AIO
- Stock Information
- Founded
- ZYME 2003
- AIO 2019
- Country
- ZYME United States
- AIO United States
- Employees
- ZYME N/A
- AIO N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- AIO Finance/Investors Services
- Sector
- ZYME Health Care
- AIO Finance
- Exchange
- ZYME Nasdaq
- AIO Nasdaq
- Market Cap
- ZYME 751.6M
- AIO 760.3M
- IPO Year
- ZYME 2017
- AIO N/A
- Fundamental
- Price
- ZYME $15.39
- AIO $22.46
- Analyst Decision
- ZYME Buy
- AIO
- Analyst Count
- ZYME 5
- AIO 0
- Target Price
- ZYME $19.00
- AIO N/A
- AVG Volume (30 Days)
- ZYME 572.6K
- AIO 141.5K
- Earning Date
- ZYME 10-31-2024
- AIO 01-01-0001
- Dividend Yield
- ZYME N/A
- AIO 9.05%
- EPS Growth
- ZYME N/A
- AIO N/A
- EPS
- ZYME N/A
- AIO N/A
- Revenue
- ZYME $62,199,000.00
- AIO N/A
- Revenue This Year
- ZYME $30.09
- AIO N/A
- Revenue Next Year
- ZYME N/A
- AIO N/A
- P/E Ratio
- ZYME N/A
- AIO N/A
- Revenue Growth
- ZYME N/A
- AIO N/A
- 52 Week Low
- ZYME $7.80
- AIO $15.09
- 52 Week High
- ZYME $17.70
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- ZYME 55.74
- AIO 48.53
- Support Level
- ZYME $12.39
- AIO $22.00
- Resistance Level
- ZYME $17.70
- AIO $23.94
- Average True Range (ATR)
- ZYME 0.84
- AIO 0.49
- MACD
- ZYME 0.10
- AIO -0.03
- Stochastic Oscillator
- ZYME 56.50
- AIO 23.71
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.